编码次级淋巴组织趋化因子和肿瘤裂解物的树突状细胞疫苗对小鼠前列腺癌的抗肿瘤免疫作用

Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.

作者信息

Lu Jun, Zhang Qi, Liang Chun-Min, Xia Shu-Jie, Zhong Cui-Ping, Wang Da-Wei

机构信息

Department of Urology, Shanghai Jiao Tong University, Affiliated First People's Hospital, Shanghai 200080, China.

出版信息

Asian J Androl. 2008 Nov;10(6):883-9. doi: 10.1111/j.1745-7262.2008.00431.x.

DOI:10.1111/j.1745-7262.2008.00431.x

PMID:18958352

Abstract

AIM

To investigate the antitumor immunity by a dendritic cell (DC) vaccine encoding secondary lymphoid chemokine gene and tumor lysate on murine prostate cancer.

METHODS

DC from bone marrow of C57BL/6 were transfected with a plasmid vector expressing secondary lymphoid chemokine (SLC) cDNA by Lipofectamine 2,000 liposome and tumor lysate. Total RNA extracted from SLC+lysate-DC was used to verify the expression of SLC by reverse transcriptase-polymerase chain reaction (RT-PCR). The immunotherapeutic effect of DC vaccine on murine prostate cancer was assessed.

RESULTS

We found that in the prostate tumor model of C57BL/6 mice, the administration of SLC+lysate-DC inhibited tumor growth most significantly when compared with SLC-DC, lysate-DC, DC or phosphate buffer solution (PBS) counterparts (P < 0.01). Immunohistochemical fluorescent staining analysis showed the infiltration of more CD4(+), CD8(+) T cell and CD11c(+) DC within established tumor treated by SLC+lysate-DC vaccine than other DC vaccines (P < 0.01).

CONCLUSION

DC vaccine encoding secondary lymphoid chemokine and tumor lysate can elicit significant antitumor immunity by infiltration of CD4(+), CD8(+) T cell and DC, which might provide a potential immunotherapy method for prostate cancer.

摘要

目的

研究编码二级淋巴组织趋化因子基因和肿瘤裂解物的树突状细胞（DC）疫苗对小鼠前列腺癌的抗肿瘤免疫作用。

方法

用脂质体2000将表达二级淋巴组织趋化因子（SLC）cDNA的质粒载体转染至C57BL/6小鼠骨髓来源的DC，并加入肿瘤裂解物。从SLC+裂解物-DC中提取的总RNA用于通过逆转录-聚合酶链反应（RT-PCR）验证SLC的表达。评估DC疫苗对小鼠前列腺癌的免疫治疗效果。

结果

我们发现，在C57BL/6小鼠的前列腺肿瘤模型中，与SLC-DC、裂解物-DC、DC或磷酸盐缓冲液（PBS）对照组相比，给予SLC+裂解物-DC最显著地抑制了肿瘤生长（P<0.01）。免疫组织化学荧光染色分析显示，与其他DC疫苗相比，SLC+裂解物-DC疫苗治疗的已建立肿瘤内浸润的CD4(+)、CD8(+)T细胞和CD11c(+)DC更多（P<0.01）。